Kurt Rasmussen
Affiliations: | Eli Lilly, Indianapolis, IN, United States |
Google:
"Kurt Rasmussen"Mean distance: 14.85 (cluster 19) | S | N | B | C | P |
Children
Sign in to add trainee| Matthew A. Seager | post-doc | 2002-2005 | |
| Gavin Stewart Dawe | research scientist | 2000-2001 | Eli Lilly |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Marek GJ, Cunningham KA, Rasmussen K. (2019) Translating Pharmacology into Therapeutics to Fight the Opioid Crisis. The Journal of Pharmacology and Experimental Therapeutics. 371: 394-395 |
| Balcer OM, Seager MA, Gleason SD, et al. (2018) Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278 |
| Witkin JM, Mitchell S, Wafford K, et al. (2017) Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist, in Rodents: Evidence Supporting Use for the Treatment of Depression. The Journal of Pharmacology and Experimental Therapeutics |
| Kato AS, Burris KD, Gardinier KM, et al. (2016) Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism. Nature Medicine |
| Witkin JM, Monn JA, Schoepp DD, et al. (2016) The Rapidly-Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. The Journal of Pharmacology and Experimental Therapeutics |
| Fell MJ, Katner JS, Rasmussen K, et al. (2012) Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade. Frontiers in Psychiatry. 3: 49 |
| Fell MJ, Witkin JM, Falcone JF, et al. (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. The Journal of Pharmacology and Experimental Therapeutics. 336: 165-77 |
| Gehlert DR, Rasmussen K, Shaw J, et al. (2009) Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. The Journal of Pharmacology and Experimental Therapeutics. 329: 429-38 |
| Verma V, Rasmussen K, Dawe GS. (2006) Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex. Neuroscience. 143: 573-85 |
| Rasmussen K, Benvenga MJ, Bymaster FP, et al. (2005) Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. The Journal of Pharmacology and Experimental Therapeutics. 315: 1265-77 |